Table 1.
NASH drugs in phase 2 and 3 development
| Drug | Mode of action | ClinicalTrials.gov number |
|---|---|---|
| Phase 3 | ||
| Obeticholic acid | Farnesoid X receptor agonist |
NCT02548351 (REGENERATE) NCT03439254 (REVERSE) |
| Elafibranor | Peroxisome proliferator-activated receptor-alpha and -delta agonist | NCT02704403 (RESOLVE-IT) |
| Cenicriviroc | Inhibitor of CC chemokine receptors 2 and 5 | NCT03028740 (AURORA) |
| Resmetirom | Thyroid hormone receptor-beta agonist | NCT03900429 (MAESTRO-NASH) |
| Phase 2 | ||
| Aramchol | Fatty acid bile acid conjugate | NCT02279524 |
| Cilofexor | Farnesoid X receptor agonist | NCT02854605 |
| Tropifexor | Farnesoid X receptor agonist | NCT02855164 |
| EDP-305 | Farnesoid X receptor agonist | NCT03421431 |
| Pegbelfermin | Fibroblast growth factor 21 analogue | NCT03486899 |
| NGM282 | Fibroblast growth factor 19 analogue | NCT03912532 |
| Firsocostat | Acetyl-CoA carboxylase inhibitor | NCT02856555 |
| PF-05221304 | Acetyl-CoA carboxylase inhibitor | NCT03248882 |
| Liraglutide | Glucagon-like peptide-1 agonist | NCT01237119 |
| Semaglutide | Glucagon-like peptide-1 agonist | NCT02970942 |
| Lanifibranor | Peroxisome proliferator-activated receptor-alpha agonist | NCT03008070 |
| Seladelpar | Peroxisome proliferator-activated receptor-delta agonist | NCT03551522 |
| Saroglitazar | Peroxisome proliferator-activated receptor-alpha and -gamma agonist | NCT03061721 |
| MSDC-0602K | Mitochondrial pyruvate carrier inhibitor | NCT02784444 |
| VK2809 | Thyroid hormone receptor-beta agonist | NCT02927184 |